Targeting Novel Paths
to Halt Fibrotic Diseases and Cancers
Novel paradigm to overcome aggressive fibrosis and treatment resistance
Massalia Therapeutics is a preclinical-stage biotechnology company developing a sole-in-class therapeutic platform at the interface of fibrosis, neoplasm and neovascularization. The company’s scientific platform was developed from leaders with strong clinical oncology backgrounds, combining deep insights into the molecular mechanisms driving fibrosis, neoplasm and neovascularization and the targeting of the SANF (Soluble Angiogenic Neoplastic and Fibrotic) factor.
Massalia Therapeutics is poised to advance a pipeline of first-in-class therapies that address unmet medical needs across multiple disease indications.